

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

OS-RC-2

RRID:CVCL_1626

Type: Cell Line

Proper Citation

RRID:CVCL_1626

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1626

Proper Citation: RRID:CVCL_1626

Description: Cell line OS-RC-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Clear cell renal cell carcinoma

Defining Citation: [PMID:4008433](#), [PMID:14534724](#), [PMID:15604581](#), [PMID:20164919](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28489074](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OS-RC-2

Synonyms: OSRC2, RC-2

Cross References: BTO:BTO_0002403, CLO:CLO_0050889, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:512, BioSample:SAMN03472222, BioSample:SAMN10987712, cancercellines:CVCL_1626, CCRID:1101HUM-PUMC000292, CCRID:3101HUMTCHu40, Cell_Model_Passport:SIDM00239, ChEMBL-Cells:ChEMBL3308274, ChEMBL-Targets:ChEMBL2366188, CLS:305086, Cosmic:909250, Cosmic-CLP:909250, DepMap:ACH-000159, EGA:EGAS00001000978, FANTOM5_SSTAR:10411-106B6, GDSC:909250, GEO:GSM1670310, IARC_TP53:21604, KCB:KCB 200779YJ,

LiGeA:CCLE_815, LINCS_LDP:LCL-1768, PharmacDB:OSRC2_1203_2019, PRIDE:PXD030304, Progenetix:CVCL_1626, PubChem_Cell_line:CVCL_1626, RCB:RCB0735, Wikidata:Q54936539

ID: CVCL_1626

Record Creation Time: 20220427T221400+0000

Record Last Update: 20260913T005657+0000

Ratings and Alerts

No rating or validation information has been found for OS-RC-2.

No alerts have been found for OS-RC-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 178 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Liu Y, et al. (2026) Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. Cell death & disease, 17(1).

Shi H, et al. (2026) OSCAR functions as a collagen I receptor to suppress hippo signaling and reprogram lipid metabolism in clear-cell renal cell carcinoma. Cell death & disease, 17(1).

Heritz JA, et al. (2026) Targeting and dissociating HIF2? from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer. Communications medicine, 6(1), 91.

Yang T, et al. (2026) Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(42), e20237.

Sun S, et al. (2026) Enhancing CAR-T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF-Mediated Angiogenesis. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(42), e21975.

Zhang Q, et al. (2025) The extracellular-matrix-remodeling capability exposes therapeutic vulnerability in a subset of renal cell carcinomas with tumor thrombi. Developmental cell.

Jiang Q, et al. (2025) HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. Cell, 188(7), 1807.

Shirole NH, et al. (2025) Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer. *Cancer discovery*, 15(7), 1484.

Luo Q, et al. (2025) PUMA reduces FASN ubiquitination to promote lipid accumulation and tumor progression in human clear cell renal cell carcinoma. *Cell death & disease*, 16(1), 460.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

Liu Y, et al. (2024) A1CF Binding to the p65 Interaction Site on NKRF Decreased IFN- γ Expression and p65 Phosphorylation (Ser536) in Renal Carcinoma Cells. *International journal of molecular sciences*, 25(7).

Yin L, et al. (2024) ACE Loss Drives Renal Cell Carcinoma Growth and Invasion by Modulating AKT-FOXO1. *Biologics : targets & therapy*, 18, 397.

Xu S, et al. (2024) Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response. *EBioMedicine*, 104, 105162.

Cheng B, et al. (2023) Vascular mimicry induced by m6A mediated IGFL2-AS1/AR axis contributes to pazopanib resistance in clear cell renal cell carcinoma. *Cell death discovery*, 9(1), 121.

Li T, et al. (2023) CircZBTB44 promotes renal carcinoma progression by stabilizing HK3 mRNA structure. *Molecular cancer*, 22(1), 77.

Yuan Y, et al. (2023) FBXO30 functions as a tumor suppressor and an E3 ubiquitin ligase for hZIP1-mediated HIF-1 α degradation in renal cell carcinoma. *International journal of oncology*, 62(3).

Shen C, et al. (2023) Biochemical and clinical effects of RPS20 expression in renal clear cell carcinoma. *Oncology reports*, 49(1).

Wang Y, et al. (2023) A pan-cancer analysis of the expression and molecular mechanism of DHX9 in human cancers. *Frontiers in pharmacology*, 14, 1153067.

Ma S, et al. (2023) A novel gene signature related to oxidative stress predicts the prognosis in clear cell renal cell carcinoma. *PeerJ*, 11, e14784.

Zhang W, et al. (2023) piRNA-1742 promotes renal cell carcinoma malignancy by regulating USP8 stability through binding to hnRNPU and thereby inhibiting MUC12 ubiquitination. *Experimental & molecular medicine*, 55(6), 1258.